NCT06794996: An ongoing trial by Vertex Pharmaceuticals Incorporated
This trial is ongoing. It must report results 2 years, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06794996 |
|---|---|
| Title | A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidney Disease |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 4, 2025 |
| Completion date | Dec. 30, 2026 |
| Required reporting date | Dec. 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 12, 2025 |
| Days late | None |